Johnson & Johnson Overcoming Pharma Pricing Pressure
Image Source: Johnson & Johnson fourth quarter presentation Johnson & Johnson’s ‘Pharmaceutical’ segment continues to deliver top-line growth despite ongoing headwinds related to net price decreases in the US pharma space. The company remains one of our favorite dividend growth ideas as its higher-growth ‘Pharmaceutical’ segment is augmented by a solid ‘Consumer’ business and improving ‘Medical Devices’ business. By Kris Rosemann Simulated newsletter portfolio idea Johnson & Johnson (JNJ) is simply a powerhouse, but that does not mean its shares are immune to broader market volatility, global economic expectations, and headline risk. While the final of those factors via ongoing legal issues has provided an overhang on shares of the consumer and pharmaceutical giant, its track record of consistency cannot … Read more